Irinotecan liposomes + ADEBRELIMAB + LENVATINIB + LEUCOVORIN CALCIUM + Fluorouracil for cholangiocarcinoma

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Trial registered. A trial in people is registered. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 18 Oct 2024: Trial registered, NCT06648525

The trials

NCT06648525: Adebrelimab Combined with Irinotecan Liposomes, 5-FU, CF ± Lenvatinib As First-line Treatment for Advanced ICC

State
Not started
Phase
Phase 2
People
68 planned
Started
Oct 2024
Primary completion
Apr 2027
Arms
Group A: Adebrelimab+Irinotecan liposomes+5-fluorouracil+calcium folinate+lenvatinib
Results
None posted
  1. 18 Oct 2024: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Trial registered

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.